CAM
PCRX icon

Cormorant Asset Management’s Pacira BioSciences PCRX Stock Holding History

Cormorant Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-50,000
Closed -$3.5M – 58
2014
Q1 		$3.5M Hold
50,000
– – 0.8% 36
2013
Q4 		$2.88M Buy
+50,000
New +$2.63M 0.83% 24

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Cormorant Asset Management's PCRX Position: Q2 2014 in Review

Cormorant Asset Management sold out of Pacira BioSciences (PCRX) in Q2 2014, closing a stake of 50,000 shares — an estimated $3.5M sold.

Cormorant Asset Management first reported a position in PCRX in Q4 2013 and held it in 2 quarters. The position peaked at $3.5M in Q1 2014. 191 funds tracked by Wall St. Rank hold PCRX as of Q2 2014.

  • Cormorant Asset Management reported no remaining Pacira BioSciences position as of Q2 2014 after selling out during the quarter.
  • Cormorant Asset Management sold 50,000 Pacira BioSciences shares in Q2 2014, an estimated $3.5M.
  • Cormorant Asset Management first reported a position in Pacira BioSciences in Q4 2013 and held it in 2 quarters.
  • Cormorant Asset Management's Pacira BioSciences position peaked at $3.5M in Q1 2014.
  • 191 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2014.

Based on Cormorant Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.